Overview

AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine if AMG 853 is effective compared with placebo as measured by change in Asthma Control Questionnaire (ACQ) composite symptoms scores from baseline to week 12.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen